CEO: Uceris ulcerative colitis OK gives Santarus 'strong momentum' in new year
This article was originally published in Scrip
Executive Summary
Investors greeted the FDA's approval of Santarus' ulcerative colitis drug Uceris (budesonide) by driving shares of the company up as high as 16% on 15 January, before the stock closed at $12.52, a gain of $1.24, or 11%.